Molecule

The VSV-GP oncolytic virus platform is an engineered oncolytic virus built upon a chimeric VSV with its surface protein replaced by the GP of the lymphocytic choriomeningitis virus. This engineered oncolytic virus is designed to mitigate the risk of neurotoxicity and neurotoxicity and lower the risk of developing neutralizing antibodies, allowing repeated intra-tumoral and systemic administration^1,2

Proposed MoA

The VSV-GP is intended to induce immunogenic cell death in tumors susceptible to type I interferon and stimulate immune cell recruitment into tumors (turning cold tumors into hot tumors).^1,2 Tumor cell–specific antigens are released via oncolysis, which, together with innate immune activation, induces anti-tumor activity. Furthermore, the VSV-GP does not integrate into the human genome.

The viral platform can be armed with additional therapeutic genes (gene cargos). The local expression of gene cargos at the tumor site may enhance VSV-GP–mediated antitumor immune response.

Gene cargos can be introduced into the viral genome.² The local expression of gene cargos at the tumor site may enhance VSV-GP–mediated anti-tumor immune response.⁴

Combination rationale

The VSV-GP has shown preclinical activity in a wide variety of solid cancer types, as well as synergy when combined with PD-1 blockade.^1–4
 

Proposed MoA^1,2

zoom

Proposed MoA^1,2

Zoom